首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.
【24h】

Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.

机译:外源性表面活性剂(钙表面活性剂)在小儿急性肺损伤中的作用:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Despite evidence that patients with acute lung injury (ALI) have pulmonary surfactant dysfunction, trials of several surfactant preparations to treat adults with ALI have not been successful. Preliminary studies in children with ALI have shown that instillation of a natural lung surfactant (calfactant) containing high levels of surfactant-specific protein B may be beneficial. OBJECTIVE: To determine if endotracheal instillation of calfactant in infants, children, and adolescents with ALI would shorten the course of respiratory failure. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, blinded trial of calfactant compared with placebo in 153 infants, children, and adolescents with respiratory failure from ALI conducted from July 2000 to July 2003. Twenty-one tertiary care pediatric intensive care units participated. Entry criteria included age 1 week to 21 years, enrollment within 48 hours of endotracheal intubation, radiological evidence of bilateral lung disease, and an oxygenation index higher than 7. Premature infants and children with preexisting lung, cardiac, or central nervous system disease were excluded. INTERVENTION: Treatment with intratracheal instillation of 2 doses of 80 mL/m2 calfactant or an equal volume of air placebo administered 12 hours apart. MAIN OUTCOME MEASURES: Ventilator-free days and mortality; secondary outcome measures were hospital course, adverse events, and failure of conventional mechanical ventilation. RESULTS: The calfactant group experienced an acute mean (SD) decrease in oxygenation index from 20 (12.9) to 13.9 (9.6) after 12 hours compared with the placebo group's decrease from 20.5 (14.7) to 15.1 (9.0) (P = .01). Mortality was significantly greater in the placebo group compared with the calfactant group (27/75 vs 15/77; odds ratio, 2.32; 95% confidence interval, 1.15-4.85), although ventilator-free days were not different. More patients in the placebo group did not respond to conventional mechanical ventilation. There were no differences in long-term complications. CONCLUSIONS: Calfactant acutely improved oxygenation and significantly decreased mortality in infants, children, and adolescents with ALI although no significant decrease in the course of respiratory failure measured by duration of ventilator therapy, intensive care unit, or hospital stay was observed.
机译:背景:尽管有证据表明患有急性肺损伤(ALI)的患者患有肺表面活性剂功能障碍,但用于治疗成人ALI的几种表面活性剂制剂的试验并未成功。对ALI儿童的初步研究表明,滴注含有高水平表面活性剂特异性蛋白B的天然肺表面活性剂(钙表面活性剂)可能是有益的。目的:确定气管内滴注小钙剂是否可用于患有ALI的婴儿,儿童和青少年,以缩短呼吸衰竭的进程。设计,地点和患者:2000年7月至2003年7月,对153名ALI因呼吸衰竭的婴儿,儿童和青少年进行了镇定剂与安慰剂比较的多中心,随机,盲法试验。二十一个三级护理小儿重症监护室参加了该试验。 。入选标准包括1周至21岁的年龄,气管插管的48小时内入组,双侧肺部疾病的放射学证据以及氧合指数高于7。排除早产儿和患肺,心脏或中枢神经系统疾病的早产儿。干预:气管内滴注2剂80 mL / m2钙表面活性剂或等量的空气安慰剂,间隔12小时给药。主要观察指标:无呼吸机日和死亡率。次要结果指标是医院病程,不良事件和常规机械通气失败。结果:在12小时后,无钙活性剂组的氧合指数从20(12.9)降至13.9(9.6)的急性平均(SD)降低,而安慰剂组从20.5(14.7)降至15.1(9.0)(P = 0.01) )。安慰剂组的死亡率显着高于无钙活性剂组(27/75 vs 15/77;优势比,2.32; 95%置信区间,1.15-4.85),但无呼吸机的天数无差异。安慰剂组中更多的患者对常规机械通气没有反应。长期并发症无差异。结论:尽管通过呼吸机治疗,重症监护病房或住院时间可观察到呼吸衰竭的发生率没有明显降低,但表面活性剂可明显改善ALI婴儿,儿童和青少年的氧合作用并显着降低死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号